LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Incyte Corp

Fechado

SetorSaúde

63.22 0.83

Visão Geral

Variação de preço das ações

24h

Atual

Mín

62.23

Máximo

63.45

Indicadores-chave

By Trading Economics

Rendimento

-43M

158M

Vendas

-126M

1.1B

P/E

Médio do Setor

304.25

56.602

EPS

1.16

Margem de lucro

15.025

Funcionários

2,617

EBITDA

-80M

257M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+17.69% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-4.3B

12B

Abertura anterior

62.39

Fecho anterior

63.22

Sentimento de Notícias

By Acuity

29%

71%

74 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de mai. de 2025, 19:39 UTC

Grandes Movimentos do Mercado

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 de mai. de 2025, 23:18 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 de mai. de 2025, 22:30 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- Update

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de mai. de 2025, 21:54 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 de mai. de 2025, 21:22 UTC

Conversa de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 de mai. de 2025, 21:17 UTC

Conversa de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 de mai. de 2025, 21:17 UTC

Principais Notícias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 de mai. de 2025, 21:05 UTC

Conversa de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 de mai. de 2025, 20:55 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de mai. de 2025, 20:37 UTC

Principais Notícias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 de mai. de 2025, 20:33 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 de mai. de 2025, 20:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 de mai. de 2025, 20:18 UTC

Principais Notícias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 de mai. de 2025, 20:16 UTC

Principais Notícias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 de mai. de 2025, 20:15 UTC

Ganhos

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 de mai. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: William K. Daniel Joins Board

16 de mai. de 2025, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: Strategic Investment by KKR Completed

16 de mai. de 2025, 20:05 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 19:38 UTC

Conversa de Mercado

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 de mai. de 2025, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 de mai. de 2025, 18:51 UTC

Principais Notícias

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 de mai. de 2025, 18:41 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 18:37 UTC

Conversa de Mercado

Gold Futures End Week on Negative Note -- Market Talk

16 de mai. de 2025, 18:35 UTC

Principais Notícias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 de mai. de 2025, 18:32 UTC

Principais Notícias

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 de mai. de 2025, 18:28 UTC

Conversa de Mercado

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

17.69% parte superior

Previsão para 12 meses

Média 73.86 USD  17.69%

Máximo 95 USD

Mínimo 52 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

6

Comprar

11

Manter

1

Vender

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

74 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation